5-(N,N-dimethyl)-Amiloride Hydrochloride: A Precision NHE1 Inhibitor for Cardiac and Endothelial Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA) is a crystalline inhibitor of Na+/H+ exchanger isoforms NHE1, NHE2, and NHE3, with potent Ki values (0.02–14 μM) enabling selective targeting of intracellular pH regulation pathways in mammalian cells (APExBIO). DMA blocks sodium influx and proton extrusion, influencing sodium balance and protecting cardiac tissue from ischemia-reperfusion injury through normalization of tissue sodium (Chen et al. 2021). The compound shows minimal inhibition of NHE4, NHE5, and NHE7, supporting its use in isoform-specific research. DMA also inhibits ouabain-sensitive ATPases and alanine uptake in hepatocytes, highlighting broader roles in ion transport. This review details the mechanism, benchmarks, and integration parameters of DMA for advanced cardiovascular and endothelial research.

Biological Rationale

Intracellular pH and sodium ion homeostasis are fundamental to mammalian cell function. The Na+/H+ exchangers (NHEs) mediate electroneutral exchange of intracellular H+ for extracellular Na+, directly impacting pH, cell volume, and signaling. NHE1 is the predominant isoform in cardiac and vascular endothelial cells, and its dysregulation contributes to cellular injury in pathological states such as ischemia, reperfusion, and sepsis (Chen et al. 2021). Inhibition of NHE1 and related isoforms allows precise experimental modulation of these processes, facilitating studies of contractile dysfunction, cytoskeletal signaling, and vascular permeability. 5-(N,N-dimethyl)-Amiloride hydrochloride (DMA) offers high selectivity and potency for NHE1, NHE2, and NHE3, making it an indispensable reagent for dissecting sodium/proton exchange and its downstream effects.

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA is a synthetic derivative of amiloride, structurally modified to enhance NHE isoform inhibition. It binds to the extracellular face of NHE1, NHE2, and NHE3, blocking Na+ influx and H+ efflux. The compound’s Ki values reflect its potency: 0.02 μM for NHE1, 0.25 μM for NHE2, and 14 μM for NHE3, with negligible impact on NHE4, NHE5, or NHE7 at typical experimental concentrations (APExBIO). By inhibiting these exchangers, DMA alters intracellular pH, reduces sodium loading, and prevents the activation of pH-sensitive signaling cascades. In cardiac cells, this mechanism mitigates calcium overload and contractile dysfunction during ischemia-reperfusion. DMA also inhibits ouabain-sensitive ATP hydrolysis and sodium-potassium ATPase activity in rat liver membranes, and suppresses alanine uptake in hepatocytes, indicating broader effects on ion-coupled transporters.

Evidence & Benchmarks

• DMA exhibits a Ki of 0.02 μM for NHE1, 0.25 μM for NHE2, and 14 μM for NHE3, enabling selective inhibition of these isoforms (APExBIO).
• In cardiac ischemia-reperfusion models, DMA normalizes tissue sodium levels and protects against contractile dysfunction (Chen et al. 2021, Figure 2).
• DMA has minimal effect on NHE4, NHE5, and NHE7 at concentrations effective for NHE1–3 (APExBIO).
• DMA inhibits ouabain-sensitive ATP hydrolysis and sodium-potassium ATPase in rat liver plasma membranes (APExBIO).
• DMA reduces alanine uptake in hepatocytes, reflecting its impact on broader sodium-coupled transport processes (APExBIO).
• DMA is soluble at up to 30 mg/ml in DMSO and dimethyl formamide; solutions should be prepared fresh and stored at -20°C (APExBIO).

For advanced mechanistic insights and translational relevance, see this review, which extends our discussion by focusing on signaling and experimental design. This article uniquely benchmarks isoform specificity and practical integration for cardiovascular research, building on overviews such as this protocol-driven examination.

Applications, Limits & Misconceptions

DMA is used to inhibit Na+/H+ exchanger activity in studies of intracellular pH regulation, sodium transport, and cell volume control. Its high NHE1 selectivity makes it valuable for dissecting cardiac and endothelial cell function during pathologies such as ischemia-reperfusion and sepsis. The reagent also supports analysis of ouabain-sensitive transport and metabolic flux in hepatocytes. However, DMA is not a pan-NHE inhibitor and has limited efficacy on NHE4, NHE5, and NHE7. Additionally, its effects on other sodium-coupled transporters must be considered in metabolic studies.

Common Pitfalls or Misconceptions

• DMA is not effective against all NHE isoforms: It shows minimal inhibition of NHE4, NHE5, and NHE7 at standard research concentrations.
• DMA is not suitable for in vivo diagnostic or medical use: It is for research use only and not approved for clinical applications.
• Long-term storage of solutions is not recommended: Prepare solutions fresh and use promptly to ensure potency.
• DMA may inhibit other sodium-coupled transporters: Effects on ATPases and amino acid uptake must be controlled for in multi-pathway studies.
• Solubility limitations in aqueous buffers: DMA is best dissolved in DMSO or DMF, not water.

Workflow Integration & Parameters

DMA (C3505) from APExBIO should be dissolved in DMSO or dimethyl formamide at up to 30 mg/ml. Working concentrations for NHE1 inhibition typically range from 0.01–1 μM, depending on cell type and assay. For cardiac or endothelial models, preincubation for 10–30 minutes at 37°C is standard. Solutions should be stored at -20°C and used within 24 hours to maintain activity (APExBIO). For a detailed experimental strategy and troubleshooting, see this protocol article (provides actionable tips not covered here).

For nuanced discussion on integrating DMA into biomarker and pathophysiology workflows, this article clarifies broader implications in endothelial and cardiac injury models, contrasting our focus on mechanistic inhibition and benchmark specificity.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride hydrochloride is a validated, highly selective Na+/H+ exchanger inhibitor enabling robust investigation of intracellular pH regulation, sodium transport, and contractile physiology. Its integration into cardiovascular and endothelial injury models is underpinned by precise isoform targeting and compatibility with metabolic assays. APExBIO’s C3505 provides reproducible quality for advanced research needs, but limitations regarding isoform selectivity and storage must be observed. The ongoing characterization of endothelial biomarkers such as moesin further highlights the translational value of DMA-enabled models (Chen et al. 2021). For additional advanced mechanistic perspectives, see our linked reviews and protocols.